-1.png?width=1000&height=628&name=Home%20Testing%20Blog%20(8)-1.png)
.png?width=1800&height=1000&name=Home%20Testing%20Blog%20(7).png)
GLP1s
Tirzepatide UK
Mounjaro
GLP1s
Tirzepatide UK
Mounjaro
GLP‑1s & Addiction: Can They Reduce Smoking, Alcohol & Drug Cravings?
.png?width=48&height=48&name=Untitled%20design%20(23).png){kind=small}
TribeTeam
Why This Matters Now
Emerging research shows that GLP-1 receptor agonists could affect brain reward pathways -- the same circuits involved in addiction. This has triggered a surge in searches like "GLP-1s and smoking cessation" and "can GLP-1 meds reduce alcohol cravings?"
How GLP-1s May Influence Addiction Pathways
GLP-1 receptors exist not only in the gut but also in parts of the brain's reward circuitry. They may modulate dopamine and reward sensitivity, which are central to substance use disorders.
Large Real-World Evidence
A major observational study of over 600,000 U.S. Veterans found that people taking GLP-1s had significantly lower risks of substance use disorders, including:
-18%
Alcohol
-14%
Cannabis
-20%
Nicotine and Cocaine
-25%
Opioids
Compared to people on other diabetes drugs.
People already struggling with addiction had fewer overdoses, lower hospital visits, and lower mortality.
This suggests that GLP-1s may reduce both the risk of developing addiction and the severity of addiction-related outcomes, although causation is not yet proven.
Smaller, Controlled Clinical Evidence
A systematic review shows:
GLP-1 receptor agonists are associated with lower rates of alcohol-related events in observational cohorts.
Randomised clinical trials showed non-significant trends toward reduced alcohol consumption and cravings, indicating more research is needed before clinical addiction treatment recommendations can be made.
Evidence on Smoking and Other Addictions
While less data exist:
- GLP-1 signaling affects dopamine pathways linked with nicotine reward.
- Small lab and RCT data indicate potential reductions in cigarette intake and reward responses, but more evidence is needed.
Note on anecdotal reports
Many users report dramatically reduced alcohol or smoking cravings on forums, but these are personal anecdotes, not clinical proof.
Bottom Line
Research is promising but preliminary. GLP-1 medications show potential to reduce alcohol and drug addiction behaviours by modulating brain reward systems, but stronger randomised clinical trials are essential before prescribing them as addiction treatments.
Supporting your body during weight loss treatment can make all the difference. From vitamins to collagen support, we've got you covered.
Ready to support your journey? Here's what we stock at TribElle.
-2.png?width=1600&height=800&name=Home%20Testing%20Blog%20(6)-2.png)